Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short-term Investments (2016 - 2024)

Historic Short-term Investments for Myriad Genetics (MYGN) over the last 15 years, with Q2 2024 value amounting to $4.9 million.

  • Myriad Genetics' Short-term Investments fell 7393.62% to $4.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $4.9 million, marking a year-over-year decrease of 7393.62%. This contributed to the annual value of $8.8 million for FY2023, which is 8482.76% down from last year.
  • Per Myriad Genetics' latest filing, its Short-term Investments stood at $4.9 million for Q2 2024, which was down 7393.62% from $7.4 million recorded in Q1 2024.
  • In the past 5 years, Myriad Genetics' Short-term Investments ranged from a high of $103.2 million in Q1 2022 and a low of $4.9 million during Q2 2024
  • Its 5-year average for Short-term Investments is $46.4 million, with a median of $44.0 million in 2020.
  • Per our database at Business Quant, Myriad Genetics' Short-term Investments skyrocketed by 27941.18% in 2022 and then plummeted by 8751.52% in 2023.
  • Quarter analysis of 5 years shows Myriad Genetics' Short-term Investments stood at $33.7 million in 2020, then soared by 141.54% to $81.4 million in 2021, then dropped by 28.75% to $58.0 million in 2022, then tumbled by 84.83% to $8.8 million in 2023, then plummeted by 44.32% to $4.9 million in 2024.
  • Its last three reported values are $4.9 million in Q2 2024, $7.4 million for Q1 2024, and $8.8 million during Q4 2023.